Norsulfazol Kupro (Sulfathiazole)

Sulfathiazole blocks the bacterial enzyme dihydropteroate synthase, competing with para‑aminobenzoic acid (PABA). This inhibition stops the synthesis of folic acid, a vitamin essential for bacterial DNA production, resulting in a bacteriostatic effect that limits infection.

The dosage and frequency of Norsulfazol Kupro are determined by the prescribing healthcare professional based on the type and severity of the skin infection, patient age, and other clinical factors. Patients should follow the prescriber’s instructions precisely.

Safety data for sulfathiazole in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Norsulfazol Kupro, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other topical antibiotics such as mupirocin or fusidic acid, sulfathiazole offers a broad‑spectrum sulfonamide activity against many Gram‑positive and some Gram‑negative bacteria. Its mechanism differs by targeting folic acid synthesis, which can be advantageous in cases of resistance to protein synthesis inhibitors.

Store Norsulfazol Kupro at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight, and extreme temperatures to maintain stability and efficacy.

Norsulfazol Kupro is applied topically to the affected skin area. The prescribed amount is spread thinly over the lesion, usually once or twice daily, and gently massaged until absorbed. Hands should be washed before and after application.

Serious risks include severe allergic reactions such as Stevens‑Johnson syndrome, toxic epidermal necrolysis, systemic hypersensitivity, and hemolysis in patients with G6PD deficiency. Immediate medical attention is required if symptoms like widespread rash, blistering, fever, or mucosal involvement occur.

Individuals with a known hypersensitivity to sulfathiazole, other sulfonamides, or any component of the formulation should avoid using Norsulfazol Kupro. It is also contraindicated in patients with severe G6PD deficiency due to the risk of hemolysis.